Cynthia Wu1, Dhruva J Dwivedi, Laura Pepler, Zakhar Lysov, John Waye, Jim Julian, Karl Desch, David Ginsburg, Jeffrey I Weitz, Clive Kearon, Patricia C Liaw. 1. From the Department of Clinical Hematology, University of Alberta, Edmonton, Alberta, Canada (C.W.); Departments of Medicine (D.J.D., J.I.W., C.K., P.C.L.), Department of Medical Sciences (L.P., Z.L.), Department of Pathology and Molecular Medicine (J.W.), and Oncology (J.J.), Thrombosis and Atherosclerosis Research Institute (D.J.D., L.P., Z.L., J.I.W., P.C.L.), McMaster University, Hamilton, Ontario, Canada; and Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, Michigan (K.D., D.G.).
Abstract
OBJECTIVE: The interaction of protein C (PC) with the endothelial PC receptor (EPCR) enhances activated PC generation. We performed targeted gene sequencing of the PC gene (PROC) and EPCR genes (PROCR) in patients with unprovoked venous thromboembolism (VTE) to determine whether mutations that impair PC-EPCR interactions are associated with an increased risk of VTE. APPROACH AND RESULTS: We sequenced exon 3 of PROC and exons 2 and 3 of PROCR (the exons that encode the protein-protein binding domains of PC and EPCR) in 653 patients with unprovoked VTE and in 627 healthy controls. Five single nucleotide variants, each in individual patients, were identified that result in abnormal PC (Arg9Cys, Val34Met, and Arg-1Cys) or abnormal EPCR proteins (Arg96Cys and Val170Leu). We did not detect any nonsynonymous coding variants in the controls. When the PC variants were expressed in human embryonic kidney 293 cells, all exhibited decreased synthesis, and 2 of the variants had reduced capacity for activated PC generation. When expressed on the surface of human embryonic kidney 293 cells, the EPCR variants showed reduced affinity for fluorescently labeled PC. In addition, the previously reported EPCR A3 haplotype, which promotes cellular shedding of EPCR, is over-represented in the patient group (P=0.001). CONCLUSIONS: This is the first targeted DNA sequencing analysis of PROC and PROCR in a large group of patients with unprovoked VTE. Our data suggest that mutations that impair PC-EPCR interactions may be associated with an increased risk of VTE.
OBJECTIVE: The interaction of protein C (PC) with the endothelial PC receptor (EPCR) enhances activated PC generation. We performed targeted gene sequencing of the PC gene (PROC) and EPCR genes (PROCR) in patients with unprovoked venous thromboembolism (VTE) to determine whether mutations that impair PC-EPCR interactions are associated with an increased risk of VTE. APPROACH AND RESULTS: We sequenced exon 3 of PROC and exons 2 and 3 of PROCR (the exons that encode the protein-protein binding domains of PC and EPCR) in 653 patients with unprovoked VTE and in 627 healthy controls. Five single nucleotide variants, each in individual patients, were identified that result in abnormal PC (Arg9Cys, Val34Met, and Arg-1Cys) or abnormal EPCR proteins (Arg96Cys and Val170Leu). We did not detect any nonsynonymous coding variants in the controls. When the PC variants were expressed in humanembryonic kidney 293 cells, all exhibited decreased synthesis, and 2 of the variants had reduced capacity for activated PC generation. When expressed on the surface of humanembryonic kidney 293 cells, the EPCR variants showed reduced affinity for fluorescently labeled PC. In addition, the previously reported EPCR A3 haplotype, which promotes cellular shedding of EPCR, is over-represented in the patient group (P=0.001). CONCLUSIONS: This is the first targeted DNA sequencing analysis of PROC and PROCR in a large group of patients with unprovoked VTE. Our data suggest that mutations that impair PC-EPCR interactions may be associated with an increased risk of VTE.
Entities:
Keywords:
endothelial cell protein C receptor; genes; polymorphism, genetic; protein C; venous thromboembolism
Authors: Weihong Tang; Martina Teichert; Daniel I Chasman; John A Heit; Pierre-Emmanuel Morange; Guo Li; Bruno H Ch Stricker; Paul M Ridker; Aaron R Folsom; Nicholas L Smith; Nathan Pankratz; Frank W Leebeek; Guillaume Paré; Mariza de Andrade; Christophe Tzourio; Bruce M Psaty; Saonli Basu; Rikje Ruiter; Lynda Rose; Sebastian M Armasu; Thomas Lumley; Susan R Heckbert; André G Uitterlinden; Mark Lathrop; Kenneth M Rice; Mary Cushman; Albert Hofman; Jean-Charles Lambert; Nicole L Glazer; James S Pankow; Jacqueline C Witteman; Philippe Amouyel; Joshua C Bis; Edwin G Bovill; Xiaoxiao Kong; Russell P Tracy; Eric Boerwinkle; Jerome I Rotter; David-Alexandre Trégouët; Daan W Loth Journal: Genet Epidemiol Date: 2013-05-05 Impact factor: 2.135
Authors: J A Heit; S M Armasu; Y W Asmann; J M Cunningham; M E Matsumoto; T M Petterson; M De Andrade Journal: J Thromb Haemost Date: 2012-08 Impact factor: 5.824
Authors: Clive Kearon; Jim A Julian; Michael J Kovacs; David R Anderson; Philip Wells; Betsy Mackinnon; Jeffrey I Weitz; Mark A Crowther; Sean Dolan; Alexander G Turpie; William Geerts; Susan Solymoss; Paul van Nguyen; Christine Demers; Susan R Kahn; Jeannine Kassis; Marc Rodger; Julie Hambleton; Michael Gent; Jeffrey S Ginsberg Journal: Blood Date: 2008-09-12 Impact factor: 22.113
Authors: Weihong Tang; Mary Rachel Stimson; Saonli Basu; Susan R Heckbert; Mary Cushman; James S Pankow; Aaron R Folsom; Nathan Pankratz Journal: J Thromb Haemost Date: 2019-12-06 Impact factor: 5.824
Authors: José Manuel Soria; Pierre-Emmanuel Morange; Joan Vila; Juan Carlos Souto; Manel Moyano; David-Alexandre Trégouët; José Mateo; Noémi Saut; Eduardo Salas; Roberto Elosua Journal: J Am Heart Assoc Date: 2014-10-23 Impact factor: 5.501